Zilebesiran

Zilebesiran is an experimental small interfering RNA developed by Roche and Alnylam that is administered subcutaneously twice annually to lower blood pressure in people already taking other antihypertensive drugs.^[1]^[2]^[3] It works by impeding the synthesis of angiotensinogen in the liver.^[4]^[5]

References

^ Carvalho, Thiago (2023). "RNA interference treatment targeting angiotensinogen lowers blood pressure". Nature Medicine. 29 (12): 2962–2963. doi:10.1038/d41591-023-00091-x. ISSN 1078-8956. PMID 37845541.
^ Khan, Rida S.; Frishman, William H. (22 February 2024). "Zilebesiran: A Promising Antihypertensive Therapy Inhibiting Angiotensinogen Synthesis". Cardiology in Review. doi:10.1097/CRD.0000000000000645. PMID 38385680.
^ Waldron, James (5 March 2024). "2nd win for Alnylam RNAi blood pressure med strengthens Roche's $2.8B biobucks bet". Fierce Biotech. Retrieved 6 March 2024.
^ Desai, Akshay S.; Webb, David J.; Taubel, Jorg; Casey, Sarah; Cheng, Yansong; Robbie, Gabriel J.; et al. (20 July 2023). "Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension" (PDF). New England Journal of Medicine. 389 (3): 228–238. doi:10.1056/NEJMoa2208391. hdl:20.500.11820/9ec1c393-058a-4fe7-8e8f-df207dcdfb85. PMID 37467498.
^ Bakris, George L.; Saxena, Manish; Gupta, Anil; Chalhoub, Fadi; Lee, Jongtae; Stiglitz, Daniel; et al. (5 March 2024). "RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial". JAMA. 331 (9): 740–749. doi:10.1001/jama.2024.0728. PMC 10873804. PMID 38363577.